Exhibit 107
Calculation of Filing Fee Tables
SCHEDULE TO
ALPINE IMMUNE SCIENCES, INC.
(Name of Subject Company (Issuer))
ADAMS MERGER SUB, INC.
(Offeror)
a wholly owned subsidiary of
VERTEX PHARMACEUTICALS INCORPORATED
(Parent of Offeror)
(Names of Filing Persons (identifying status as offeror, issuer or other person))
Table 1-Transaction Valuation
| Transaction Valuation* | Fee Rate** | Amount of Filing Fee | ||||
Fees to Be Paid | $4,945,909,007.89 | 0.00014760 | $730,016.17 | |||
Fees Previously Paid | $ 0 | $ 0 | ||||
Total Transaction Valuation | $4,945,909,007.89 | |||||
Total Fees Due for Filing | $730,016.17 | |||||
Total Fees Previously Paid | $ 0 | |||||
Total Fee Offsets | $ 0 | |||||
Net Fee Due | $730,016.17 | |||||
| * | Estimated solely for purposes of calculating the amount of the filing fee only. The transaction valuation was calculated by adding: |
| (a) | the product of (i) $65.00, the purchase price per share (the “Offer Price”) of Alpine Immune Sciences, Inc. (“Alpine”) common stock, par value $0.001 per share (each such share, a “Share”), net to the seller in cash, without interest thereon and subject to any applicable tax withholding, and (ii) 65,603,313 Shares issued and outstanding; |
| (b) | the product of (i) 8,562,404 Shares issuable pursuant to outstanding options with an exercise price less than the Offer Price and (ii) $53.82, the difference between the Offer Price and $11.18, the weighted average exercise price for such options; |
| (c) | the product of (i) 457,705 Shares issuable pursuant to outstanding restricted stock units and (ii) the Offer Price; |
| (d) | the product of (i) 7,069 Shares issuable pursuant to outstanding warrants to purchase Shares with a $12.38 exercise price and (ii) $52.62, the difference between the Offer Price and the exercise price for such warrants; |
| (e) | the product of (i) 34,722 Shares issuable pursuant to outstanding warrants to purchase Shares with a $4.32 exercise price and (ii) $60.68, the difference between the Offer Price and the exercise price for such warrants; and |
| (f) | the product of (i) 2,902,127 Shares issuable pursuant to outstanding warrants to purchase Shares with a $0.001 exercise price and (ii) $64.999, the difference between the Offer Price and the exercise price for such warrants. |
The calculation of the filing fee is based on information provided by Alpine as of April 18, 2024.
| ** | The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #1 for fiscal year 2024 beginning on October 1, 2023, issued August 25, 2023, by multiplying the transaction value by 0.00014760. |